Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5547389 | 0.89 | HSD17B3 (0.51) | L3MBTL1HSD17B3CES2CES1STS | |
| SCHEMBL5548382 | 0.88 | HSD17B3 (0.53) | L3MBTL1HSD17B3CES2CES1STS | |
| SCHEMBL8106430 | 0.86 | HSD17B3 (0.54) | L3MBTL1HSD17B3CES2CES1STS | |
| SCHEMBL687760 | 0.85 | MAPT (0.46) | HPGDL3MBTL1SMN1; SMN2CES2CES1 | |
| SCHEMBL28043023 | 0.83 | TDP1 (0.39) | HPGDL3MBTL1SMN1; SMN2CES1MAPT | |
| SCHEMBL28622337 | 0.81 | MAPT (0.39) | HPGDL3MBTL1SMN1; SMN2MAPTLMNA | |
| SCHEMBL28780268 | 0.79 | L3MBTL1 (0.44) | L3MBTL1SMN1; SMN2MAPTLMNATDP1 | |
| SCHEMBL4926756 | 0.79 | CES1 (0.37) | HPGDL3MBTL1SMN1; SMN2CES2CES1 | |
| Butyrophenone SCHEMBL27921458 | 0.78 | L3MBTL1 (0.74) | HPGDL3MBTL1SMN1; SMN2HSD17B3CES2 | |
| SCHEMBL27558025 | 0.78 | CES2 (0.35) | HPGDL3MBTL1SMN1; SMN2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105906591-A | Synthesis method of 2-amino-gamma-butyrolactone hydrochloride | 中国药科大学 | 2016-08-31 | — | — | CN | claimed |
| CN-102653543-A | Preparation method, biological activity and application of 3-substituted type Jolkinolide compound | UNIV CHINA PHARMA | 2012-09-05 | — | — | CN | claimed |
| CN-105906591-A | Synthesis method of 2-amino-gamma-butyrolactone hydrochloride | 中国药科大学 | 2016-08-31 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102653543-A | Preparation method, biological activity and application of 3-substituted type Jolkinolide compound | UNIV CHINA PHARMA | 2012-09-05 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0420464-B1 | 3-Isoxazolone derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1994-07-13 | — | — | EP | disclosed |
| US-5321037-A | Isoxazole derivatives for use as cerebro-active drugs and central muscle relaxants | SANKYO COMPANY, LIMITED (JP) | 1994-06-14 | — | — | US | disclosed |
| EP-0335723-B1 | ISOXAZOLE DERIVATIVES FOR USE AS CEREBRO-ACTIVE DRUGS AND CENTRAL MUSCLE RELAXANTS | Sankyo Company Limited (JP) | 1991-12-04 | — | — | EP | disclosed |
| EP-0420464-A2 | 3-Isoxazolone derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1991-04-03 | — | — | EP | disclosed |
| EP-0335723-A1 | Isoxazole derivatives for use as cerebro-active drugs and central muscle relaxants | Sankyo Company Limited (JP) | 1989-10-04 | — | — | EP | disclosed |
| US-4619932-A | CENTRAL NERVOUS SYSTEM CONTROLLERS; ANTI-SCHIZOPHRENIA AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-28 | — | — | US | disclosed |
| US-4567187-A | CENTRAL NERVOUS SYSTEM | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-28 | — | — | US | disclosed |
| US-4460593-A | Carbostyril derivatives, and central nervous system controlling agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-17 | — | — | US | disclosed |
| US-4455422-A | ANTIHISTAMINES, CNS CONTROLLERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HPGD 3159/4885L3MBTL1 1931/4885SMN1; SMN2 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.